{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:49:34Z","timestamp":1774676974545,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":477,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cmi.2022.07.022","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T23:25:38Z","timestamp":1659655538000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ceftriaxone versus ampicillin for the treatment of community-acquired pneumonia. A propensity matched cohort study"],"prefix":"10.1016","volume":"29","author":[{"given":"Dmitri","family":"Guz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maayan","family":"Bracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotam","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dror","family":"Kozlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Avni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.07.022_bib1","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib2","series-title":"Community acquired pneumonia: controversies and questions, an issue of infectious disease clinics","author":"File","year":"2013"},{"key":"10.1016\/j.cmi.2022.07.022_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/infdis\/174.5.986","article-title":"The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the centers for disease control and prevention\u2019s pneumococcal sentinel surveillance system","volume":"174","author":"Butler","year":"1996","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.022_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/48.4.463","article-title":"The problem with cephalosporins","volume":"48","author":"Dancer","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.07.022_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MAJ.0b013e318294833f","article-title":"Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009","volume":"347","author":"Berger","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cmi.2022.07.022_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jiph.2021.05.018","article-title":"Antibiotic prescribing patterns for hospitalized children with community-acquired pneumonia in a secondary care center","volume":"14","author":"Albuhairi","year":"2021","journal-title":"J\u00a0Infect Public Health"},{"key":"10.1016\/j.cmi.2022.07.022_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00006454-199510000-00013","article-title":"Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease","volume":"14","author":"Friedland","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2022.07.022_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib9","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00006454-199610000-00030","article-title":"Epidemiology and in\u00a0vitro susceptibility of drug-resistant Streptococcus pneumoniae","volume":"15","author":"Appelbaum","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2022.07.022_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1714562","article-title":"Aspiration pneumonia","volume":"380","author":"Mandell","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2022.07.022_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10096-018-3228-4","article-title":"Molecular-based diagnosis of Clostridium difficile infection is associated with reduced mortality","volume":"37","author":"Avni","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.022_bib13","first-page":"1","article-title":"Multivariate and propensity score matching software with automated balance optimization: the matching package for R","volume":"42","author":"Sekhon","year":"2011","journal-title":"J\u00a0Stat Soft"},{"key":"10.1016\/j.cmi.2022.07.022_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/10618600.1993.10474623","article-title":"Comparison of multivariate matching methods: structures, distances, and algorithms","volume":"2","author":"Gu","year":"1993","journal-title":"J\u00a0Comput Graph Stat"},{"key":"10.1016\/j.cmi.2022.07.022_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1183\/09031936.00128107","article-title":"Early mortality in patients with community-acquired pneumonia: causes and risk factors","volume":"32","author":"Garcia-Vidal","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2022.07.022_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCOUTCOMES.109.875658","article-title":"Missing data analysis using multiple imputation: getting to the heart of the matter","volume":"3","author":"He","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cmi.2022.07.022_bib17","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib18","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ajic.2014.03.038","article-title":"Impact of an antimicrobial stewardship program on the length of stay of patients admitted to hospital with community-acquired pneumonia","volume":"42","author":"DiDiodato","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2022.07.022_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1465-9921-14-44","article-title":"Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH","volume":"14","author":"Blasi","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.cmi.2022.07.022_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5694\/j.1326-5377.1998.tb138964.x","article-title":"Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults?","volume":"168","author":"Paterson","year":"1998","journal-title":"Med J Aust"},{"key":"10.1016\/j.cmi.2022.07.022_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clinthera.2005.06.009","article-title":"Therapeutic options for pneumococcal pneumonia in Turkey","volume":"27","author":"Oncu","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2022.07.022_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1086\/381886","article-title":"Drug-resistant pneumococcal pneumonia: clinical relevance and related factors","volume":"38","author":"Aspa","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.022_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199408113310607","article-title":"Management of infections caused by antibiotic-resistant Streptococcus pneumoniae","volume":"331","author":"Friedland","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1128\/CMR.11.4.628","article-title":"Management of infections due to antibiotic-resistant Streptococcus pneumoniae","volume":"11","author":"Kaplan","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2022.07.022_bib25","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.07.022_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijid.2019.06.013","article-title":"Hospital-onset adult invasive pneumococcal disease in Israel: sicker patients, different pathogens","volume":"85","author":"Kenig","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.022_bib27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cmi.2018.06.021","article-title":"Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?","volume":"24","author":"Batard","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.07.022_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12890-020-01198-4","article-title":"Comparison of ceftriaxone plus macrolide and ampicillin\/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial","volume":"20","author":"Hamao","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/thx.2006.067371","article-title":"The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia","volume":"62","author":"Barlow","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2022.07.022_bib30","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1007\/s10096-012-1693-8","article-title":"CURB-65 score predicted mortality in community-acquired pneumonia better than IDSA\/ATS minor criteria in a low-mortality-rate setting","volume":"31","author":"Guo","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.022_bib31","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.07.022_bib33","first-page":"CD004418","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults","volume":"2012","author":"Eliakim-Raz","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22003901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22003901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:53Z","timestamp":1761118433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22003901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1198743X22003901"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.07.022","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftriaxone versus ampicillin for the treatment of community-acquired pneumonia. A propensity matched cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}